Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Novo Nordisk invests €432m in Irish tablet plant
Novo Nordisk is refitting its facility in Athlone, Ireland, aimed at expanding GLP-1 manufacturing capacity.
3 Mar 2026
Illness Severity Alters Sepsis Survival Risk in AKI Patients
Sepsis may worsen or improve AKI survival depending on illness severity, new data suggest. Explore how risk reverses in the sickest patients. Read more.
3 Mar 2026
RSV Vaccination Guidance for Immunocompromised Patients
IDSA guidelines recommend RSV vaccination for immunocompromised adults, and advise individualized timing plus shared decisions now.
3 Mar 2026
New GLP-1 Pill Outperforms Oral Semaglutide in Blood Glucose Levels
A new non-peptide GLP-1 pill proved more effective for weight loss than oral semaglutide in a recent Phase III trial.
3 Mar 2026
Chronic Headaches Tied to Higher Rates of Depression and Anxiety
Adults with chronic headaches are nearly five times more likely to have clinical symptoms of depression, and at a more than seven times higher risk of clinical anxiety.
3 Mar 2026
Erection Pills Under-Prescribed in Patients with Prostate Cancer
First-line treatments for erectile dysfunction are under-prescribed in patients with prostate cancer, despite favourable clinical outcomes.
3 Mar 2026
Major Depressive Disorder: Biomarkers in Brain and Blood Identified
Shared molecular changes in brain and blood may improve major depressive disorder diagnosis and guide personalised therapies.
3 Mar 2026
Long COVID Drives Subchronic Lung and Brain Injury
A mouse long COVID model associates breathlessness with postinfectious fibrotic lung remodeling and neuroinflammation following clearance.
3 Mar 2026
A New Approach to Chest-X-Ray Imaging: Landmark Identification in AI Enabled ‘Smart Collimation Thorax’
Smart Collimation Thorax AI model development, validation, and performance results...
New contender enters oral weight loss drug race
The study suggests that the novel compound may offer superior glycaemic control and weight reduction compared with current GLP-1 drugs.
1
2
3
4
…
1,502
1,503
1,504
→
We’ve noticed you’re accessing
from
North/South America.
View
View